Free scoping read. A written assessment of your manuscript in two business days, at no cost.

Start one
Contents

Academy · Research Writing · Safety vs Efficacy

The Difference Between Safety and Efficacy in Drug Research: Definitions, Reporting and Trial Phases

Efficacy refers to how well a drug performs under controlled trial conditions, and safety to the acceptability of its adverse effects at that level of performance. These are separate questions, and they are not always reported with the same completeness in the literature. Selective publication can distort the apparent efficacy of a treatment.

Pubrica AcademyWritten by a clinical research writer Reviewed bya drug safety reviewer Published10 October 2026 Last checked10 October 2026 Reading time8 minutes Sources10 peer-reviewed

Efficacy and safety are frequently discussed together in drug research, but they are separate, independently measured properties of an intervention, not components of a single verdict on whether a drug “works.” Efficacy describes how well a drug produces its intended effect under the controlled conditions of a trial; safety describes the nature, frequency and severity of its adverse effects at the doses studied. Porzsolt and colleagues' 2020 analysis in the Journal of Comparative Effectiveness Research argues that efficacy refers specifically to a drug's performance under experimental conditions, as distinct from effectiveness under real-world conditions, while the ICH's E6(R2) Good Clinical Practice guideline defines a clinical trial as an investigation conducted with the object of ascertaining safety and efficacy as two separate objectives of the same study, not a single combined outcome12.

Learning objectives

  • The definitions that distinguish efficacy from safety, and efficacy from effectiveness, in current research terminology
  • How selective publication can distort the apparent efficacy of a treatment
  • How safety and efficacy evidence accumulate differently across the phases of clinical trial development

Common misconceptions

  • “If a drug is approved, its safety and efficacy data are equally complete and were reported equally.” Selective publication can distort the apparent efficacy of a treatment, and research comparing regulatory submissions with publications has found that efficacy and safety outcomes are not always reported with the same completeness.

Definitions of efficacy and safety

Efficacy is the degree to which a drug produces its intended result under the controlled, closely monitored conditions of a clinical trial, typically a randomised, often placebo-controlled study with a defined patient population, dosing schedule and outcome measure specified in advance. Porzsolt and colleagues describe this as “the proof of principle under experimental conditions,” and distinguish it from effectiveness, the drug's performance under the more varied, less controlled conditions of routine clinical practice; they argue that this distinction is frequently blurred both in reporting standards and in everyday use of the two terms1. Their analysis of eleven methodological reviews found that none fully explained all of the related key terms and that efficacy and effectiveness were often mentioned without being clearly defined, which, the authors argue, makes published trial results more difficult to interpret and can render guideline recommendations based on them inconsistent1.

Safety, by contrast, is assessed through the systematic collection of adverse events, unfavourable and unintended signs, symptoms, or diseases temporally associated with the drug's use, whether or not they are judged to be caused by it. The ICH E6(R2) guideline's glossary defines an adverse event specifically as any such unfavourable occurrence in a subject administered a drug, a serious adverse event as one resulting in death, hospitalisation, disability, or a comparably serious outcome, and an adverse drug reaction as an adverse event for which a causal relationship to the drug is at least a reasonable possibility2. These categories are distinct and more granular than anything in the definition of efficacy, reflecting that safety assessment is fundamentally concerned with systematically cataloguing and grading a range of possible harms, rather than with a single pass-or-fail judgement parallel to the efficacy result.

Divergence of efficacy and safety reporting under selective publication

Selective publication can distort the apparent efficacy of a treatment. Turner and colleagues' 2008 study in the New England Journal of Medicine examined this question for antidepressant trials registered with the US Food and Drug Administration (FDA), comparing the published literature with the FDA's own classification of the trial results3. The study found that, in combination, these effects caused the published literature to present the efficacy of these drugs as substantially more favourable than the complete FDA-registered dataset supported.

Separate research has documented a related but distinct pattern in how safety data from similar trials reach publication. Rising, Bacchetti, and Bero's 2008 review of FDA-submitted trials found that efficacy outcomes were more likely than safety outcomes to be changed or omitted between a trial's FDA submission and its eventual publication, while Hart, Lundh, and Bero's 2012 BMJ reanalysis of meta-analyses found that incorporating unpublished or incompletely reported trial data could shift a pooled efficacy estimate meaningfully. These findings indicate that efficacy and safety information do not necessarily pass through the publication process at the same rate or with the same fidelity to the original trial record45. Ioannidis and colleagues' CONSORT extension for reporting harms in randomised trials was developed in direct response to this documented gap, setting out specific reporting items for adverse events that are not covered by a trial's standard reporting of its primary efficacy outcome6.

Accumulation of safety and efficacy evidence across trial phases

Because efficacy and safety are measured separately, they also accumulate at different rates and with different emphasis across the standard phases of drug development. Phase I trials are designed primarily to establish a drug's basic safety profile and tolerability in a small number of participants and to identify the dose at which adverse effects become unacceptable; efficacy is typically assessed only incidentally, if at all, at this stage. Phase II trials begin to evaluate efficacy at various doses alongside continued safety monitoring in a somewhat larger group, while Phase III trials, conducted in larger and more diverse populations, are generally the first point at which a drug's efficacy and its risk-benefit ratio are evaluated together with sufficient statistical power to support a regulatory approval decision2.

Even after approval, the two kinds of evidence continue to accumulate on different trajectories. Efficacy evidence from Phase III trials is generally considered close to final at the point of approval, since the regulatory decision depends on it directly, whereas safety evidence continues to accumulate through Phase IV post-marketing surveillance, because rare adverse events may not appear in a pre-approval trial population too small to detect them. The World Medical Association's Declaration of Helsinki provides the ethical foundation for this continued safety monitoring, holding that research involving human subjects carries an ongoing obligation to protect participants' welfare that does not end once a drug reaches the market; this obligation underlies the post-marketing safety-surveillance system that continues to generate safety data long after a drug's core efficacy case has been established7. The ICH's E9 guideline on statistical principles for clinical trials reinforces the same asymmetry from the statistical side, noting that efficacy analyses are generally built around a small number of pre-specified primary endpoints decided before the trial begins, while safety analyses are necessarily broader and more exploratory, since adverse events cannot all be anticipated and pre-specified in the same way8.

Reporting safety and efficacy in a manuscript or protocol

Because efficacy and safety are measured, analysed and reported through different mechanisms, a manuscript or protocol that treats them with equal explicitness in its structure is less likely to reproduce an imbalance between the reporting of the two outcome types. The CONSORT 2010 statement's broader reporting framework for randomised trials requires both outcome types to be pre-specified in the trial's methods section before unblinding, which is itself a safeguard against the selective emphasis that may arise once results are known; the specific CONSORT harms extension builds on this by setting out separate reporting items for how adverse events should be defined, collected and presented, items that have no equivalent in the standard efficacy-outcome reporting checklist96.

In scientific writing, this means that a results section discussing a drug's performance should generally avoid language that conflates the two, such as describing a drug simply as “effective and well-tolerated” in a single sentence without separating what the efficacy data showed from what the safety data showed, and at what dose or in which subgroup each finding applied. PRISMA 2020's broader reporting principles, developed for systematic reviews but reflecting the same logic, call for distinct outcome domains to be separated in a results summary rather than merged into a single narrative conclusion, so that a reader can judge each type of evidence, and its particular limitations, on its own terms10. Maintaining this separation explicitly in the text can considerably improve the accuracy with which a paper's abstract and conclusions represent the two distinct bodies of evidence that a drug trial produces.

Key points

Key points

Efficacy and safety are separate measurements — the performance of a drug under controlled trial conditions and the acceptability of its adverse effects — that accumulate on different timelines across drug development and are not always reported with the same completeness. Selective publication can distort the apparent efficacy of a treatment.

Practical application

Practical application

  1. Efficacy and safety should be reported as distinct outcomes with distinct reporting standards. The CONSORT harms extension should be used specifically for adverse-event reporting, rather than safety being treated as a secondary note under the efficacy results.
  2. Trial registry entries should be checked against the published report for both efficacy and safety outcomes. Such a comparison can reveal selective reporting that the published paper alone would not disclose.
  3. Efficacy should be distinguished explicitly from effectiveness when trial evidence is summarised. Authors should state whether a finding derives from controlled trial conditions (efficacy) or real-world use (effectiveness), since Porzsolt and colleagues found that this distinction is frequently blurred in practice.

Frequently asked questions

Yes. Efficacy and safety are independent measurements, and a drug can show a strong intended effect while also showing an adverse-event profile severe or frequent enough to limit or prevent its approval or use.

No. Porzsolt and colleagues' analysis defines efficacy as performance under controlled trial conditions and effectiveness as performance under real-world conditions, treating the two as a dichotomy rather than interchangeable terms or points on a single continuum.

Documented research, including Rising, Bacchetti, and Bero's 2008 review, has found that efficacy and safety outcomes are not always reported with the same completeness between a trial's regulatory submission and its eventual publication, which is part of why dedicated reporting standards like the CONSORT harms extension were developed.

It generally is not, even after approval; rare adverse events can remain undetected until a drug reaches a much larger population through Phase IV post-marketing surveillance, which is why safety evidence continues to accumulate on a different timeline from the efficacy case made for approval.

References

  1. Porzsolt F, Wiedemann F, Phlippen M, Weiss C, Weiss M, Schmaling K, Kaplan RM. The terminology conflict on efficacy and effectiveness in healthcare. Journal of Comparative Effectiveness Research. 2020;9(17):1171-1178. read 10 October 2026. View on Journal of Comparative Effectiveness Research
  2. International Council for Harmonisation. ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). European Medicines Agency, EMA/CHMP/ICH/135/1995. read 10 October 2026. View on EMA
  3. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. New England Journal of Medicine. 2008;358(3):252-260. read 10 October 2026. View on New England Journal of Medicine
  4. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLOS Medicine. 2008;5(11):e217. read 10 October 2026. View on PLOS Medicine
  5. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012;344:d7202. read 10 October 2026. View on The BMJ
  6. Ioannidis JPA, Evans SJW, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D; CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine. 2004;141(10):781-788. read 10 October 2026. View on Annals of Internal Medicine
  7. World Medical Association. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-2194. read 10 October 2026. View on JAMA
  8. International Council for Harmonisation. ICH Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9. read 10 October 2026. View on ICH
  9. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. read 10 October 2026. View on The BMJ
  10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. read 10 October 2026. View on The BMJ

Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.

How to cite this article

Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.

Pubrica Academy. (2026, October 10). The Difference Between Safety and Efficacy in Drug Research: Definitions, Reporting and Trial Phases. Pubrica. https://pubrica.com/academy/safety-and-efficacy-in-drug-research/

This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.

Efficacy vs. Safety Reporting Checklist

This checklist may be used when writing up or evaluating trial evidence that addresses both efficacy and safety.

[ ] Defined efficacy, effectiveness, and safety as separate terms before reporting results
[ ] Checked the trial registry entry against the published report for both outcome types
[ ] Applied the CONSORT harms extension for adverse-event reporting specifically
[ ] Noted the trial phase and what that implies about how complete the safety picture is
[ ] Avoided treating a positive efficacy result as implying an acceptable safety profile, or vice versa

Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.

How Pubrica can help

Pubrica’s clinical writing team reports efficacy and safety findings as separate evidentiary tracks, cross-checked against trial registries and written to current CONSORT and ICH standards.

Find something else

Search the Pubrica Academy

Access is free and requires no account. Enter a topic, or open the full library to filter by category, sub-topic or resource type.

Pubrica can review a manuscript to ensure that safety is reported with the same rigour as efficacy.

A scoping assessment is free and takes two business days. It provides a written assessment of what the work requires and which specialist would undertake it.

Get a free quote

Regulations

Check your project against this rule

  1. 1Your work
  2. 2Your details
  3. 3Send
What do you need?

Material you send is held under signed confidentiality, with access limited to the assigned team and encrypted transfer. It is not used to train anything and is not passed to third-party tools. Ask for the agreement before you send anything you would rather cover first.